Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Technical Presentation (May 2020)
22 slides from Genocea Biosciences's technical presentation, May 12, 2020
Slide 1: GEN-011: Transforming T cell therapy for solid tumors
GEN-011: Transforming T cell therapy for solid tumors KOL Symposium 12 May 2020
Slide 2: GEN-011: Designed to improve upon TIL therapy
GEN-011: Designed to improve upon TIL therapy T cells targeting the right tumor neoantigens Peripheral blood T cells enabling greater activity and durability Robust and rapidly scalable manufacturing process 2
Slide 3: TIL therapy: Current gold standard for solid tumor cell therapy
TIL therapy: Current gold standard for solid tumor cell therapy Tumor-infiltrating lymphocyte (TIL) 2,3,4 CAR-T therapy Unproven in solid tumors TCR-transduced (TCR-T) Limited clinical validation HLA-limited Durable efficacy Potential safety concerns1 in checkpoint-refractory patients 1. Linette et
Slide 4: Lessons learned: Drivers of TIL therapy clinical success
Lessons learned: Drivers of TIL therapy clinical success Target multiple tumor neoantigens • Amplify existing anti-tumor T cell responses • More neoantigens combats tumor heterogeneity, limits tumor escape Deploy both CD4+ and CD8+ T cells • CD4+ T cells provide critical support to CD8+ T cells CD4+
Slide 5: GEN-011 – a new category of neoantigen T cell therapy
GEN-011 – a new category of neoantigen T cell therapy: Peripheral blood-derived, ATLAS™-powered Peripheral blood (leukopak) GEN-011 Up to 30 neoantigens Neoantigen-specific cell expansion in fully closed single-use vessels Autologous, non-engineered 5
Slide 6: GEN-011: Embraces TIL advantages, overcomes limitations
GEN-011: Embraces TIL advantages, overcomes limitations TIL limitations GEN-011 GEN-011 advantages Neoantigen • Targets up to 30 relevant neoantigens with selection via + + • Limited tumor specificity CD4 and CD8 memory T cells • Cannot avoid inhibitory, • Avoids pro-tumor Inhibigens™ that may be de
Slide 7: Neoantigen selection with ATLAS
Neoantigen selection with 448 ATLAS #2 genocea
Slide 8: ATLAS empirically selects the relevant neoantigens of tumor-specific T cell responses
ATLAS empirically selects the relevant neoantigens of tumor-specific T cell responses Comprehensive identification of Tumor NGS Unique Bacterial vectors biopsy analysis plasmids for expressing each Autologous patient- and every candidate dendritic cell tumor-relevant T candidate cell responses neoan
Slide 9: ATLAS enables identification of neoantigens to which CD8+ and CD4+ T cells respond
ATLAS enables identification of neoantigens to which CD8+ and CD4+ T cells appropriately respond CD8+ T cells CD4+ T cells Neoantigens Background responses Concentration Concentration IFN IFN Inhibigens Normalized to Background Control Background Normalized to Control Background Normalized to In
Slide 10: Identification and exclusion of Inhibigens is critical for cancer immunotherapies
Identification and exclusion of Inhibigens is critical for cancer immunotherapies 1,600 Adjuvant only 1,000 Adjuvant only ) 1,400 Protective vaccine ) 3 3 Inhibigens + Adjuvant m Protective vaccine + Inhibigen m 800 1,200 m ( m ( e 1,000 e 600 m m u l u 800 l o v o v r 400 600 o r o m u 400 m T u 20
Slide 11: GEN-011 manufacturing process and drug product profile
GEN-011 manufacturing process and drug product profile 11
Slide 12: GEN-011 uses peripheral blood T cells
GEN-011 uses peripheral blood T cells T cells from PBL are readily accessible, non-exhausted, and contain relevant neoantigen specificities TIL limitations Recent landmark publications demonstrate the relevance of PBLs • Incomplete coverage of Antigen Experienced T Cells from Peripheral Blood tumor
Slide 13: Robust and rapidly scalable manufacturing process with fully closed single-use technology
Robust and rapidly scalable manufacturing process with fully closed single-use technology Peripheral blood Phenotypic cell sort (leukopak) GEN-011 Process Peripheral blood ensures starting cell material T cells rapidly obtained from every patient, dramatically expanding accessible patient population
Slide 14: GEN-011 delivers billions of neoantigen-specific T cells
GEN-011 delivers billions of neoantigen-specific T cells Contains an average of Majority of T cells are specific for 3.3 billion T cells ATLAS-identified neoantigens 1010 Irrelevant antigens Neoantigens CD8+ 65% r e 5% b + m CD4 u 9 n 10 l l e c T Activation Marker 2 Marker Activation 2 Marker Activ
Slide 15: GEN-011 exhibits unparalleled breadth of neoantigen coverage
GEN-011 exhibits unparalleled breadth of neoantigen coverage GEN-011 targets up to 30 neoantigens Recent selected TIL data show successful amplification to only 89% 4% of antigens included in the process1 Recent conventional TIL data show responses to an average of 6% of the predicted neoantigens2 G
Slide 16: GEN-011 T cells are highly functional and cytotoxic
GEN-011 T cells are highly functional and cytotoxic An average of 16,000 cells per T cells are potently million are secreting cytokines in cytolytic against target response to stimulation neoantigens CD8+ 100 Specific Neoantigens + 80 CD4 Unpulsed Control y t i c i 60 Negative x o t control o t y 40
Slide 17: PBL-derived T cells exhibit greater neoantigen activity and potency compared to TIL
PBL-derived T cells exhibit greater neoantigen activity and potency compared to TIL T cells are activated appropriately Neoantigen-specific T cells upon neoantigen stimulation secrete abundant IFN + 80 CD8 25000 n o i t a l u 20000 g 60 e r p L u r 15000 m / e g k r 40 p a m N 10000 F n I o i t a
Slide 18: GEN-011: CD4+ and CD8+ memory T cells for anti-tumor efficacy, persistence and proliferation
GEN-011: CD4+ and CD8+ memory T cells for anti-tumor efficacy, persistence and proliferation Pure T cell drug product Desired T cell memory phenotype Non-T cells 100 1% CD8+ y 75 c 35% n e u q 50 e CD4+ r F 65% T cells % 25 99% 0 Naive Terminal Memory memory (Cm+Em) (TEMRA) Data represent mean acros
Slide 19: GEN-011: Embraces TIL advantages, overcomes limitations
GEN-011: Embraces TIL advantages, overcomes limitations TIL limitations GEN-011 GEN-011 advantages Neoantigen • Targets up to 30 relevant neoantigens with selection via + + • Limited tumor specificity CD4 and CD8 memory T cells • Cannot avoid inhibitory, • Avoids pro-tumor Inhibigens™ that may be de
Slide 20: i<j (3) e a i) () > (3) (a) = S a3} genocea
i<j (3) e a i) () > (3) (a) 3 4 = S a3} genocea
Slide 21: Phase 1/2 pilot study of GEN-011 in refractory solid tumors
Trial Objectives Phase 1/2 pilot study of GEN-011 in refractory solid tumors Targeted Indications Cohort A Trial Objectives Melanoma, NSCLC, SCLC, Multiple low dose • Safety SCCHN, UC, RCC, SqCC skin, (up to12 patients) • Clinical activity SqCCAC • No lymphodepletion • ORR • Low dose IL-2 Tumors res
Slide 22: GEN-011: Transforming neoantigen T cell therapy for solid tumors
GEN-011: Transforming neoantigen T cell therapy for solid tumors T cells targeting the right tumor neoantigens Peripheral blood T cells enabling greater activity and durability Robust and rapidly scalable manufacturing process 22
Genocea Biosciences — Technical Presentation (May 2020) on 6ix